Interaction of endogenous endothelin-1 and inhaled nitric oxide in term and preterm infants

Clinical Science

Volumn 103, Issue SUPPL. 48, 2002, Pages

  Truog, William E ^a   Pallotto, Eugenia ^a   Clark, Perry ^a   Banks, Beverly ^a   Kaftan, Harold A ^a   Ekekezie, Ikechukwu I ^a   Norberg, Mike ^a   Ballard, Roberta A ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Chronic lung disease of prematurity; Persistent pulmonary hypertension

Indexed keywords

ENDOTHELIN 1; NITRIC OXIDE; VASODILATOR AGENT;

ARTERIAL PRESSURE; CHRONIC LUNG DISEASE; CLINICAL ARTICLE; CONFERENCE PAPER; FIBROSIS; HUMAN; INFANT; LUNG ASPIRATION; LUNG DISEASE; PATHOGENESIS; PREMATURITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; VASOCONSTRICTION; VASODILATATION;

EID: 0036672266     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs103s294s     Document Type: Conference Paper

References (9)

1. Effect of inhaled nitric oxide in endothelin-1-induced pulmonary hypertension
2. Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation. Relevance to pathogenesis of pulmonary hypertension and vascular remodeling
3. Elevated immunoreactive endothelin-1 levels in newborn infants with persistent pulmonary hypertension
4. Bronchoalveolar inflammation following airway infections in preterm infants with chronic lung disease
5. Early increase in endothelin-1 in tracheal aspirates of preterm infants: Correlation with bronchopulmonary dysplasia
6. Endothelin-1 (ET-1) and nitric oxide metabolite levels with persistent pulmonary hypertension (PPHN) treated with inhaled nitric oxide (iNO) therapy
7. Safety and efficacy of nitric oxide in chronic lung disease
8. Simplified method for purification of colostrum to obtain secretory component of immunoglobulin A, using secretory component as a reference protein in tracheal aspirate fluid
9. Financial charges and benefits of inhaled nitric oxide (INO) for ECMO-eligible infants